Literature DB >> 16009538

Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG).

Wilfried Dimpfel1.   

Abstract

Due to the electrochemical nature of the communication structure of the brain an intimate relationship between neurotransmitter activity on one side and field potentials (EEG) on the other side can be suspected. In order to learn more about this relationship pharmacological manipulation of the cholinergic transmitter system by means of agonistic and antagonistic receptor active drugs was used. Continuous recording of electrical activity from four selected brain areas (frontal cortex, hippocampus, striatum and reticular formation) in freely moving day-night converted Fisher rats was used (Tele-Stereo-EEG). Frequency analysis of telemetrically transmitted data and special definitions of frequency ranges were used to analyse the data from 45 min pre-drug and 180 min postdrug periods. Pharmacological modulation of brain activity by the selective nicotinic agonist metanicotine as well as the alpha 7 selective nicotinic antagonist methyllycaconitine revealed major changes in delta (1-4.5 Hz) and alpha2 (9-12.5 Hz) frequencies. In general blockade of the cholinergic system resulted in electrical power increases and activation in decreases. Unspecific modulation of cholinergic activity by using the cholinesterase inhibitors physostigmine, tacrine and galantamine led to alpha1 frequency (7-9.5 Hz) changes in addition to the delta and alpha2 changes. These three drugs produced a nearly identical pattern of frequency changes. Theta (4.75-6.75 Hz) and beta1 frequencies (12.75-18.5 Hz) changed to a lesser degree. A peculiar finding arose with respect to the effects of the antagonistic drugs scopolamine and biperiden since biperiden-besides the massive increase of delta and alpha1 power in common-induced a general decrease of alpha2 frequencies within all brain areas opposite to the effect of scopolamine. This special property of biperiden gives a plausible explanation for its efficacy in Parkinsonian patients since decreases of alpha2 waves in this model indicate enhancement of dopaminergic transmission [Dimpfel, W., Spüler, M., Koch, R., Schatton, W., 1987. Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats. Neuropsychobiology 18, 212-218]. Except for the effects of methyllycaconitine (p<10%) all results were statistically significant at least at the p<5% level. The results are best explained by assuming that electrical delta activity reflects cholinergic transmitter control followed by and closely linked to changes in dopaminergic transmission as indicated by additional concomitant changes in alpha2 electrical power.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009538     DOI: 10.1016/j.euroneuro.2005.03.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.

Authors:  W Dimpfel
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

2.  Hippocampal theta, gamma, and theta-gamma coupling: effects of aging, environmental change, and cholinergic activation.

Authors:  Tara K Jacobson; Matthew D Howe; Brandy Schmidt; James R Hinman; Monty A Escabí; Etan J Markus
Journal:  J Neurophysiol       Date:  2013-01-09       Impact factor: 2.714

3.  Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.

Authors:  Davide V Moretti
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

4.  Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.

Authors:  Wojciech Danysz; Gunnar Flik; Andrew McCreary; Carsten Tober; Wilfried Dimpfel; Jean C Bizot; Richard Kostrzewa; Russell W Brown; Claudia C Jatzke; Sergio Greco; Ann-Kristin Jenssen; Christopher G Parsons
Journal:  J Neural Transm (Vienna)       Date:  2015-03-22       Impact factor: 3.575

5.  Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B.

Authors:  Raphael Doenlen; Ute Krügel; Timo Wirth; Carsten Riether; Andrea Engler; Geraldine Prager; Harald Engler; Manfred Schedlowski; Gustavo Pacheco-López
Journal:  Proc Biol Sci       Date:  2010-11-24       Impact factor: 5.349

6.  Response-related sensorimotor rhythms under scopolamine and MK-801 exposures in the touchscreen visual discrimination test in rats.

Authors:  Diána Kostyalik; Kristóf Kelemen; Balázs Lendvai; István Hernádi; Viktor Román; György Lévay
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

7.  Large-Scale Circuitry Interactions Upon Earthquake Experiences Revealed by Recurrent Neural Networks.

Authors:  Han Wang; Kun Xie; Zhichao Lian; Yan Cui; Yaowu Chen; Jing Zhang; Leo Xie; Joe Tsien; Tianming Liu
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2018-10-05       Impact factor: 3.802

8.  Effect of Neurexan on the pattern of EEG frequencies in rats.

Authors:  Wilfried Dimpfel; Kerstin Roeska; Bernd Seilheimer
Journal:  BMC Complement Altern Med       Date:  2012-08-16       Impact factor: 3.659

9.  Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration.

Authors:  C M Holton; N Hanley; E Shanks; P Oxley; A McCarthy; B J Eastwood; T K Murray; A Nickerson; K A Wafford
Journal:  Alzheimers Res Ther       Date:  2020-07-15       Impact factor: 6.982

10.  Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.

Authors:  Davide V Moretti; Giovanni B Frisoni; Giuliano Binetti; Orazio Zanetti
Journal:  Front Aging Neurosci       Date:  2014-07-23       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.